North America Endocrine Disruption Screening Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Assay Type ( In-Vitro, In-Vivo ), Application ( Natural materials and Synthetic materials ), Sources of waste ( Incineration and landfill, Agricultural runoff, Industrial and municipal effluents, Pulp mill effluents, Consumer products, and Others ), Method ( Estrogen Receptor (ER) Transactivation, Androgen Receptor (AR) Transactivation, Androgen Receptor (AR) Modulation, Estrogen Receptor-alpha (ER-alpha) Binding, Estrogen Receptor-beta (ER-beta) Binding, Androgen Receptor (AR) Binding, Steroidogenesis, Aromatase Assay, and Others ), and End User ( Pharmaceutical and Biopharmaceutical companies, Cosmetics and Household Product companies, Food industry, and Chemical industry )
Market Introduction
The North America endocrine disruption screening market has been segmented into the US, Canada, and Mexico. The US held the largest share of the North America endocrine disruption screening market in 2021. Increasing adoption of technological advancements in the screening of endocrine disruption chemicals and rising research and development activities are projected to accelerate the growth of the endocrine disruption screening market. Moreover, the presence of large healthcare businesses and the growing number of hormone related cancers in North America is propelling the market's expansion in this region.
North America is highly affected due to the outbreak of the COVID-19. Countries such as the US and Canada reported the highest numbers of COVID-19 positive cases. The US registered highest number of deaths due to the COVID-19 pandemic. The chaotic situation was created in the various industry across the countries and increased the demand for diagnosis and screening devices. The life sciences segment thrives due to increased demand for in-vitro diagnostic products and rising research and development activities. Chronic diseases are common in patients at high risk of severe forms of COVID-19; however, other risk factors may also play a role. Environmental stresses, including as endocrine disrupting chemicals (EDCs), can aggravate the course of COVID-19 and contribute to the development of some chronic disorders. Several research studies have shown that patients with thyroid issues are more susceptible to the COVID 19 virus. The more severe the COVID-19, the lower the TSH and TT3 levels were, with statistical significance, according to a January 2021 research report titled "Thyroid Function Analysis in 50 Patients with COVID-19: A Retrospective Study." The severity of the condition was positively linked with the degree of declines in TSH and TT3 levels. As a result, alterations in serum TSH and TT3 levels are key symptoms of COVID-19 regimens.
Get more information on this report : 
Market Overview and Dynamics
The endocrine disruption screening market in North America is expected to grow from US$ 50,311.25 million in 2021 to US$ 61,319.50 million by 2028; it is estimated to grow at a CAGR of 2.9% from 2021 to 2028. Regulatory agencies throughout the world are grappling with the task of assessing the hazards and dangers to human and ecosystem health that may come from exposure to substances that disrupt the normal functioning of endocrine systems. The rapidly rising number of compounds in commerce, along with the dependence on conventional, expensive animal tests for hazard assessment – frequently with insufficient sensitivity to many critical processes of endocrine disruption – poses persistent problems for chemical management. As a result, there are only a few compounds for which there is enough evidence to determine whether there is endocrine toxicity, and hence only a few substances with full hazard categorization. To address this issue, regulatory assessment of endocrine disrupting chemicals (EDCs) is benefiting from a toxicology revolution focused on New Approach Methodologies (NAMs) to identify, prioritize, and assess the potential risks from chemical exposure using novel, more efficient, and mechanistically driven methodologies, and tools more rapidly.
Key Market Segments
North America endocrine disruption screening market is segmented into assay type, application, source of waste, method, end-user, and country. The North America endocrine disruption screening market, by assay type, is bifurcated into in-vitro and in-vivo. The in-vitro segment led the market in 2021. By application, the North America endocrine disruption screening market is bifurcated into natural materials and synthetic materials. In 2021. The endocrine disruption screening market, by source of waste, is segmented into incineration and landfill, agricultural runoff, industrial and municipal effluents, pulp mill effluents, consumer products, and others. In 2021, the incineration and landfill segment held the largest share of the market. The North America endocrine disruption screening market, by method, is segmented into estrogen receptor (ER) transactivation, androgen receptor (AR) transactivation, androgen receptor (AR) modulation, estrogen receptor-alpha (ER) binding, estrogen receptor beta (ER) binding, androgen receptor (AR) binding, steroidogenesis, aromatase assay, and others. In 2021, the estrogen receptor (ER) transactivation segment held the largest share of the market. The North America endocrine disruption screening market, based on end use, is segmented into pharmaceutical and biopharmaceutical companies, cosmetics and household product companies, food industry, and chemical industry. In 2021, the pharmaceutical and biopharmaceutical companies segment held the largest share of the market. Based on country, the North America endocrine disruption screening market is segmented into US, Canada, and Mexico. US held the largest market share in 2020.
Major Sources and Companies Listed
A few major primary and secondary sources referred to for preparing this report on the Endocrine Disruption Screening market in North America are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are aALPHA ANALYTICAL, Inc.; Charles River Laboratories, Inc.; Creative Bioarray; Eurofins Scientific Ltd.; JRF Global; Mérieux NutriSciences; SGS SA; and Smithers.
Reasons to buy report
- To understand the North America Endocrine Disruption Screening market landscape and identify market segments that are most likely to guarantee a strong return.
- Stay ahead of the race by comprehending the ever-changing competitive landscape for North America Endocrine Disruption Screening market.
- Efficiently plan M&A and partnership deals in North America Endocrine Disruption Screening market by identifying market segments with the most promising probable sales.
- Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form North America Endocrine Disruption Screening market.
- Obtain market revenue forecast for market by various segments from 2021-2028 in North America region.
North America Endocrine Disruption Screening Market Segmentation
North America Endocrine Disruption Screening Market - By Assay Type
- In-Vitro
- In-Vivo
North America Endocrine Disruption Screening Market - By Application
- Natural Materials
- Synthetic Materials
North America Endocrine Disruption Screening Market - By – Sources of Waste
- Incineration and Landfill
- Agricultural Runoff
- Industrial and Municipal Effluents
- Pulp Mill Effluents
- Consumer Products
- Others
North America Endocrine Disruption Screening Market - By Method
- Estrogen Receptor (ER) Transactivation
- Androgen Receptor (AR) Transactivation
- Androgen Receptor (AR) Modulation
- Estrogen Receptor-Alpha (ER-alpha) Binding
- Estrogen Receptor Beta (ER-beta) Binding
- Androgen Receptor (AR) Binding
- Steroidogenesis
- Aromatase Assay
- Others
North America Endocrine Disruption Screening Market - By End User
- Pharmaceutical and Biopharmaceutical Companies
- Chemical Industry
- Food Industry
- Cosmetics and Household Product Companies
North America Endocrine Disruption Screening Market - By Country
- US
- Canada
- Mexico
North America Endocrine Disruption Screening Market - Company Profiles
- aALPHA ANALYTICAL, Inc.
- Charles River Laboratories, Inc.
- Creative Bioarray
- Eurofins Scientific Ltd.
- JRF Global
- Mérieux NutriSciences
- SGS SA
- Smithers
1. Introduction
1.1 Study Scope
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 North America Endocrine Disruption Screening Market – By Assay Type
1.3.2 North America Endocrine Disruption Screening Market – By Application
1.3.3 North America Endocrine Disruption Screening Market – By Sources of waste
1.3.4 North America Endocrine Disruption Screening Market – By Method
1.3.5 North America Endocrine Disruption Screening Market – By End User
1.3.6 North America Endocrine Disruption Screening Market – By Country
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Endocrine Disruption Screening Market – Market Landscape
4.1 Overview
4.2 North America PEST Analysis
4.3 Experts Opinion
5. North America Endocrine Disruption Screening Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Rising Prevalence of Endocrine Disorders
5.1.2 Surging Cases of Diabetes
5.2 Market Restraints
5.2.1 Screening Technology Being Expensive
5.3 Future Trends
5.3.1 Endocrine Disrupting Through Regulatory Approaches
5.4 Impact Analysis
6. Endocrine Disruption Screening Market– North America Analysis
6.1 North America Endocrine Disruption Screening Market Revenue Forecast and Analysis
6.2 North America Endocrine Disruption Screening Market, By Country- Forecast and Analysis
7. North America Endocrine Disruption Screening Market Revenue and Forecasts To 2028– by Assay Type
7.1 Overview
7.2 North America Endocrine Disruption Screening Market, By Assay Type, 2021 & 2028 (%)
7.3 In-Virto
7.3.1 Overview
7.3.2 In-Virto: Endocrine Disruption Screening Market Revenue and Forecasts to 2028 (US$ Thousand)
7.4 In-Vivo
7.4.1 Overview
7.4.2 In-Vivo: Endocrine Disruption Screening Market Revenue and Forecasts to 2028 (US$ Thousand)
8. North America Endocrine Disruption Screening Market Revenue and Forecasts To 2028 – Application
8.1 Overview
8.2 North America Endocrine Disruption Screening Market Share by Application - 2021 & 2028 (%)
8.3 Natural Materials
8.3.1 Overview
8.3.2 Natural Materials: Endocrine Disruption Screening Market Revenue and Forecast to 2028 (US$ Thousand)
8.4 Synthetic Materials
8.4.1 Overview
8.4.2 Synthetic Materials: Endocrine Disruption Screening Market Revenue and Forecast to 2028 (US$ Thousand)
9. North America Endocrine Disruption Screening Market Revenue and Forecasts To 2028 – Sources of Waste
9.1 Overview
9.2 North America Endocrine Disruption Screening Market Share by Sources of Waste - 2021 & 2028 (%)
9.3 Incineration and landfill
9.3.1 Overview
9.3.2 Incineration and landfill: Endocrine Disruption Screening Market Revenue and Forecast to 2028 (US$ Thousand)
9.4 Agricultural runoff
9.4.1 Overview
9.4.2 Agricultural runoff: Endocrine Disruption Screening Market Revenue and Forecast to 2028 (US$ Thousand)
9.5 Industrial and Municipal Effluents
9.5.1 Overview
9.5.2 Industrial and Municipal Effluents: Endocrine Disruption Screening Market Revenue and Forecast to 2028 (US$ Thousand)
9.6 Pulp Mill Effluents
9.6.1 Overview
9.6.2 Pulp Mill Effluents: Endocrine Disruption Screening Market Revenue and Forecast to 2028 (US$ Thousand)
9.7 Consumer Products
9.7.1 Overview
9.7.2 Consumer Products: Endocrine Disruption Screening Market Revenue and Forecast to 2028 (US$ Thousand)
9.8 Others
9.8.1 Overview
9.8.2 Others: Endocrine Disruption Screening Market Revenue and Forecast to 2028 (US$ Thousand)
10. North America Endocrine Disruption Screening Market Revenue and Forecasts To 2028 – Method
10.1 Overview
10.2 North America Endocrine Disruption Screening Market Share by Method - 2021 & 2028 (%)
10.3 Estrogen Receptor (ER) Transactivation
10.3.1 Overview
10.3.2 Estrogen Receptor (ER) Transactivation: Endocrine Disruption Screening Market Revenue and Forecast to 2028 (US$ Thousand)
10.4 Androgen Receptor (AR) Transactivation
10.4.1 Overview
10.4.2 Androgen Receptor (AR) Transactivation: Endocrine Disruption Screening Market Revenue and Forecast to 2028 (US$ Thousand)
10.5 Androgen Receptor (AR) Modulation
10.5.1 Overview
10.5.2 Androgen Receptor (AR) Modulation: Endocrine Disruption Screening Market Revenue and Forecast to 2028 (US$ Thousand)
10.6 Estrogen Receptor-Alpha (ER-alpha) Binding
10.6.1 Overview
10.6.2 Estrogen Receptor-Alpha (ER-alpha) Binding: Endocrine Disruption Screening Market Revenue and Forecast to 2028 (US$ Thousand)
10.7 Estrogen Receptor beta (ER-beta) Binding
10.7.1 Overview
10.7.2 Estrogen Receptor beta (ER-beta) Binding: Endocrine Disruption Screening Market Revenue and Forecast to 2028 (US$ Thousand)
10.8 Androgen Receptor (AR) Binding
10.8.1 Overview
10.8.2 Androgen Receptor (AR) Binding: Endocrine Disruption Screening Market Revenue and Forecast to 2028 (US$ Thousand)
10.9 Steroidogenesis
10.9.1 Overview
10.9.2 Steroidogenesis: Endocrine Disruption Screening Market Revenue and Forecast to 2028 (US$ Thousand)
10.10 Aromatase Assay
10.10.1 Overview
10.10.2 Aromatase Assay: Endocrine Disruption Screening Market Revenue and Forecast to 2028 (US$ Thousand)
10.11 Others
10.11.1 Overview
10.11.2 Others: Endocrine Disruption Screening Market Revenue and Forecast to 2028 (US$ Thousand)
11. North America Endocrine Disruption Screening Market Revenue and Forecasts To 2028 – End Use
11.1 Overview
11.2 North America Endocrine Disruption Screening Market Share by End Use - 2021 & 2028 (%)
11.3 Pharmaceutical and Biopharmaceutical Companies
11.3.1 Overview
11.3.2 Pharmaceutical and Biopharmaceutical Companies: Endocrine Disruption Screening Market Revenue and Forecast to 2028 (US$ Thousand)
11.4 Cosmetics and Household Product Companies
11.4.1 Overview
11.4.2 Cosmetics and Household Product Companies: Endocrine Disruption Screening Market Revenue and Forecast to 2028 (US$ Thousand)
11.5 Food Industry
11.5.1 Overview
11.5.2 Food Industry: Endocrine Disruption Screening Market Revenue and Forecast to 2028 (US$ Thousand)
11.6 Chemical Industry
11.6.1 Overview
11.6.2 Chemical Industry: Endocrine Disruption Screening Market Revenue and Forecast to 2028 (US$ Thousand)
12. North America Endocrine Disruption Screening Market Revenue and Forecasts to 2028 – Country Analysis
12.1 North America: Endocrine Disruption Screening Market
12.1.1 Overview
12.1.2 North America: Endocrine Disruption Screening Market, by Country, 2021 & 2028 (%)
12.1.2.1 US: Endocrine Disruption Screening Market – Revenue and Forecast to 2028 (US$ Thousands)
12.1.2.1.1 Overview
12.1.2.1.2 US: Endocrine Disruption Screening Market – Revenue and Forecast to 2028 (US$ Thousands)
12.1.2.1.3 US: Endocrine Disruption Screening Market, by Assay Type, 2019–2028 (US$ Thousands)
12.1.2.1.4 US: Endocrine Disruption Screening Market, by Application, 2019–2028 (US$ Thousands)
12.1.2.1.5 US: Endocrine Disruption Screening Market, by Sources of waste, 2019–2028 (US$ Thousands)
12.1.2.1.6 US: Endocrine Disruption Screening Market, by Method, 2019–2028 (US$ Thousands)
12.1.2.1.7 US: Endocrine Disruption Screening Market, by End-user, 2019–2028 (US$ Thousands)
12.1.2.2 Canada: Endocrine Disruption Screening Market – Revenue and Forecast to 2028 (US$ Thousands)
12.1.2.2.1 Overview
12.1.2.2.2 Canada: Endocrine Disruption Screening Market – Revenue and Forecast to 2028 (US$ Thousands)
12.1.2.2.3 Canada: Endocrine Disruption Screening Market, by Assay Type, 2019–2028 (US$ Thousands)
12.1.2.2.4 Canada: Endocrine Disruption Screening Market, by Application, 2019–2028 (US$ Thousands)
12.1.2.2.5 Canada: Endocrine Disruption Screening Market, by Sources of waste, 2019–2028 (US$ Thousands)
12.1.2.2.6 Canada: Endocrine Disruption Screening Market, by Method, 2019–2028 (US$ Thousands)
12.1.2.2.7 Canada: Endocrine Disruption Screening Market, by End-user, 2019–2028 (US$ Thousands)
12.1.2.3 Mexico: Endocrine Disruption Screening Market – Revenue and Forecast to 2028 (US$ Thousands)
12.1.2.3.1 Overview
12.1.2.3.2 Mexico: Endocrine Disruption Screening Market – Revenue and Forecast to 2028 (US$ Thousands)
12.1.2.3.3 Mexico: Endocrine Disruption Screening Market, by Assay Type, 2019–2028 (US$ Thousands)
12.1.2.3.4 Mexico: Endocrine Disruption Screening Market, by Application, 2019–2028 (US$ Thousands)
12.1.2.3.5 Mexico: Endocrine Disruption Screening Market, by Sources of waste, 2019–2028 (US$ Thousands)
12.1.2.3.6 Mexico: Endocrine Disruption Screening Market, by Method, 2019–2028 (US$ Thousands)
12.1.2.3.7 Mexico: Endocrine Disruption Screening Market, by End-user, 2019–2028 (US$ Thousands)
13. Impact Of COVID-19 Pandemic on North America Endocrine Disruption Screening Market
13.1 North America: Impact Assessment of COVID-19 Pandemic
14. Endocrine Disruption Screening Market–Industry Landscape
14.1 Overview
14.2 Growth Strategies Done by the Companies in the Market (%)
14.3 Organic Developments
14.3.1 Overview
14.4 Inorganic Developments
14.4.1 Overview
15. Company Profiles
15.1 CREATIVE BIOARRAY
15.1.1 Key Facts
15.1.2 Business Description
15.1.3 Products and Services
15.1.4 Financial Overview
15.1.5 SWOT Analysis
15.1.6 Key Developments
15.2 CHARLES RIVER LABORATORIES, INC.
15.2.1 Key Facts
15.2.2 Business Description
15.2.3 Products and Services
15.2.4 Financial Overview
15.2.5 SWOT Analysis
15.2.6 Key Developments
15.3 Eurofins Scientific Ltd.
15.3.1 Key Facts
15.3.2 Business Description
15.3.3 Products and Services
15.3.4 Financial Overview
15.3.5 SWOT Analysis
15.3.6 Key Developments
15.4 SGS SA
15.4.1 Key Facts
15.4.2 Business Description
15.4.3 Products and Services
15.4.4 Financial Overview
15.4.5 SWOT Analysis
15.4.6 Key Developments
15.5 SMITHERS
15.5.1 Key Facts
15.5.2 Business Description
15.5.3 Products and Services
15.5.4 Financial Overview
15.5.5 SWOT Analysis
15.5.6 Key Developments
15.6 JRF Global
15.6.1 Key Facts
15.6.2 Business Description
15.6.3 Products and Services
15.6.4 Financial Overview
15.6.5 SWOT Analysis
15.6.6 Key Developments
15.7 Mérieux NutriSciences
15.7.1 Key Facts
15.7.2 Business Description
15.7.3 Products and Services
15.7.4 Financial Overview
15.7.5 SWOT Analysis
15.7.6 Key Developments
15.8 aALPHA ANALYTICAL, Inc.
15.8.1 Key Facts
15.8.2 Business Description
15.8.3 Products and Services
15.8.4 Financial Overview
15.8.5 SWOT Analysis
15.8.6 Key Developments
16. Appendix
16.1 About The Insight Partners
16.2 Glossary of Terms
LIST OF TABLES
Table 1. US Endocrine Disruption Screening Market, by Assay Type – Revenue and Forecast to 2028 (US$ Thousands)
Table 2. US Endocrine Disruption Screening Market, by Application – Revenue and Forecast to 2028 (US$ Thousands)
Table 3. US Endocrine Disruption Screening Market, by Sources of waste – Revenue and Forecast to 2028 (US$ Thousands)
Table 4. US Endocrine Disruption Screening Market, by Method – Revenue and Forecast to 2028 (US$ Thousands)
Table 5. US Endocrine Disruption Screening Market, by End-user – Revenue and Forecast to 2028 (US$ Thousands)
Table 6. Canada: Endocrine Disruption Screening Market, by Assay Type – Revenue and Forecast to 2028 (US$ Thousands)
Table 7. Canada Endocrine Disruption Screening Market, by Application – Revenue and Forecast to 2028 (US$ Thousands)
Table 8. Canada Endocrine Disruption Screening Market, by Sources of waste – Revenue and Forecast to 2028 (US$ Thousands)
Table 9. Canada Endocrine Disruption Screening Market, by Method – Revenue and Forecast to 2028 (US$ Thousands)
Table 10. Canada Endocrine Disruption Screening Market, by End-user – Revenue and Forecast to 2028 (US$ Thousands)
Table 11. Mexico: Endocrine Disruption Screening Market, by Assay Type – Revenue and Forecast to 2028 (US$ Thousands)
Table 12. Mexico Endocrine Disruption Screening Market, by Application – Revenue and Forecast to 2028 (US$ Thousands)
Table 13. Mexico Endocrine Disruption Screening Market, by Sources of waste – Revenue and Forecast to 2028 (US$ Thousands)
Table 14. Mexico Endocrine Disruption Screening Market, by Method – Revenue and Forecast to 2028 (US$ Thousands)
Table 15. Mexico Endocrine Disruption Screening Market, by End-user – Revenue and Forecast to 2028 (US$ Thousands)
Table 16. organic Developments Done by Companies
Table 17. Inorganic Developments Done by Companies
Table 18. Glossary of Terms
LIST OF FIGURES
Figure 1. North America Endocrine Disruption Screening Market Segmentation
Figure 2. North America Endocrine Disruption Screening Market, By Country
Figure 3. North America Endocrine Disruption Screening Market Overview
Figure 4. In-Vitro Segment Held Largest Share of Assay Type Segment in North America Endocrine Disruption Screening Market
Figure 5. US is Expected to Show Remarkable Growth During the Forecast Period
Figure 6. North America: PEST Analysis
Figure 7. Experts Opinion
Figure 8. Impact Analysis of Drivers and Restraints Pertaining to North America Endocrine Disruption Screening Market
Figure 9. North America Endocrine Disruption Screening Market – By Geography Forecast and Analysis – 2021 - 2028
Figure 10. North America Endocrine Disruption Screening Market, by Assay Type, 2021 & 2028 (%)
Figure 11. North America In-Virto: Endocrine Disruption Screening Market Revenue and Forecasts to 2028 (US$ Thousand)
Figure 12. North America In-Vivo: Endocrine Disruption Screening Market Revenue and Forecasts to 2028 (US$ Thousand)
Figure 13. North America Endocrine Disruption Screening Market Share by Application - 2021 & 2028 (%)
Figure 14. North America Natural Materials: Endocrine Disruption Screening Market Revenue and Forecasts To 2028 (US$ Thousand)
Figure 15. North America Synthetic Materials: Endocrine Disruption Screening Market Revenue and Forecasts To 2028 (US$ Thousand)
Figure 16. North America Endocrine Disruption Screening Market Share by Sources of Waste - 2021 & 2028 (%)
Figure 17. North America Incineration and landfill: Endocrine Disruption Screening Market Revenue and Forecasts To 2028 (US$ Thousand)
Figure 18. North America Agricultural runoff: Endocrine Disruption Screening Market Revenue and Forecasts To 2028 (US$ Thousand)
Figure 19. North America Industrial and Municipal Effluents: Endocrine Disruption Screening Market Revenue and Forecasts To 2028 (US$ Thousand)
Figure 20. North America Pulp Mill Effluents: Endocrine Disruption Screening Market Revenue and Forecasts To 2028 (US$ Thousand)
Figure 21. North America Consumer Products: Endocrine Disruption Screening Market Revenue and Forecasts To 2028 (US$ Thousand)
Figure 22. North America Others: Endocrine Disruption Screening Market Revenue and Forecasts To 2028 (US$ Thousand)
Figure 23. North America Endocrine Disruption Screening Market Share by Method - 2021 & 2028 (%)
Figure 24. North America Estrogen Receptor (ER) Transactivation: Endocrine Disruption Screening Market Revenue and Forecasts To 2028 (US$ Thousand)
Figure 25. North America Androgen Receptor (AR) Transactivation: Endocrine Disruption Screening Market Revenue and Forecasts To 2028 (US$ Thousand)
Figure 26. North America Androgen Receptor (AR) Modulation: Endocrine Disruption Screening Market Revenue and Forecasts To 2028 (US$ Thousand)
Figure 27. North America Estrogen Receptor-Alpha (ER-alpha) Binding: Endocrine Disruption Screening Market Revenue and Forecasts To 2028 (US$ Thousand)
Figure 28. North America Estrogen Receptor beta (ER-beta) Binding: Endocrine Disruption Screening Market Revenue and Forecasts To 2028 (US$ Thousand)
Figure 29. North America Androgen Receptor (AR) Binding: Endocrine Disruption Screening Market Revenue and Forecasts To 2028 (US$ Thousand)
Figure 30. North America Steroidogenesis: Endocrine Disruption Screening Market Revenue and Forecasts To 2028 (US$ Thousand)
Figure 31. North America Aromatase Assay: Endocrine Disruption Screening Market Revenue and Forecasts To 2028 (US$ Thousand)
Figure 32. North America Others: Endocrine Disruption Screening Market Revenue and Forecasts To 2028 (US$ Thousand)
Figure 33. North America Endocrine Disruption Screening Market Share by End Use - 2021 & 2028 (%)
Figure 34. North America Pharmaceutical and Biopharmaceutical Companies: Endocrine Disruption Screening Market Revenue and Forecasts To 2028 (US$ Thousand)
Figure 35. North America Cosmetics and Household Product Companies: Endocrine Disruption Screening Market Revenue and Forecasts To 2028 (US$ Thousand)
Figure 36. North America Food Industry: Endocrine Disruption Screening Market Revenue and Forecasts To 2028 (US$ Thousand)
Figure 37. North America Chemical Industry: Endocrine Disruption Screening Market Revenue and Forecasts To 2028 (US$ Thousand)
Figure 38. North America: Endocrine Disruption Screening Market, by Key Country – Revenue (2021) (US$ Thousands)
Figure 39. North America: Endocrine Disruption Screening Market, by Country, 2021 & 2028 (%)
Figure 40. US: Endocrine Disruption Screening Market – Revenue and Forecast to 2028 (US$ Thousands)
Figure 41. Canada: Endocrine Disruption Screening Market – Revenue and Forecast to 2028 (US$ Thousands)
Figure 42. Mexico: Endocrine Disruption Screening Market – Revenue and Forecast to 2028 (US$ Thousands)
Figure 43. Impact of COVID-19 Pandemic in North American Country Markets
Figure 44. Growth Strategies Done by the Companies in the Market (%)
- aALPHA ANALYTICAL, Inc.
- Charles River Laboratories, Inc.
- Creative Bioarray
- Eurofins Scientific Ltd.
- JRF Global
- Mérieux NutriSciences
- SGS SA
- Smithers
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the North America instrument calibrator market
- Highlights key business priorities in order to assist companies to realign their business strategies
- The key findings and recommendations highlight crucial progressive industry trends in the North America instrument calibrator market, thereby allowing players across the value chain to develop effective long-term strategies
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinize in-depth North America market trends and outlook coupled with the factors driving the instrument calibrator market, as well as those hindering it
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution